Aarti Pharmalabs Limited — Investor Meet, 20-08-2025: Analysts/Institutional Investor Meet/Con. Call Updates

Aarti Pharmalabs' Q1 FY26 standalone topline was Rs. 375 Cr (vs Rs. 394 Cr YoY), impacted by a Xanthine plant shutdown, but EBITDA rose 14% to Rs. 95 Cr and PAT 9% to Rs. 51 Cr. Consolidated topline is not comparable due to Ganesh Polychem's reclassification as a Joint Venture. Gross margins hit 57% driven by product mix and reclassification. The company maintains its 12-15% standalone EBITDA growth target for FY26. CDMO is expected to grow 35-40% this year, aiming for Rs. 800-1000 Cr revenue in 3-4 years. Xanthine capacity expands to 9000 MT, targeting Rs. 1000 Cr+ revenue. New Atali plant begins commercial production by Q2 FY26. Management expresses a confident outlook.